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ABSTRACT
Molecular profiling of  circulating tumor DNA (ctDNA) is a promising non-
invasive tool.  Here,  next-generation sequencing (NGS) of  blood-derived
ctDNA was performed in patients with advanced colorectal cancer (CRC).
We investigated  ctDNA-derived  genomic  alterations,  including  potential
actionability,  concordance  with  tissue  NGS,  and  serial  dynamics  in  78
patients with CRC using a clinical-grade NGS assay that  detects  single
nucleotide  variants  (54-73  genes)  and  selected  copy  number  variants,
fusions, and indels. Overall, 63 patients (80.8% [63/78]) harbored ctDNA
alterations; 59 (75.6% [59/78]),  ≥1 characterized alteration (variants of
unknown significance excluded). All 59 patients had actionable alterations
potentially targetable with Food and Drug Administration-approved drugs
(on-label  and/or  off-label  (N=54)  or  with  experimental  drugs in  clinical
trials  (additional  five  patients))  (University  of  California  San  Diego
Molecular Tumor Board assessment): 45, by OncoKB (http://oncokb.org/#/.
The tissue and blood concordance rates for common specific alterations
ranged from 62.3% to 86.9% (median=5 months between tests). In serial
samples  from  patients  on  anti-EGFR  therapy,  multiple  emerging
alterations  in  genes  known  to  be  involved  in  therapeutic  resistance,
including  KRAS,  NRAS,  BRAF, EGFR,  ERBB2,  and MET were detected. In
conclusion,  over  80%  of  patients  with  stage  IV  colorectal  cancer  had
detectable ctDNA, and the majority had potentially actionable alterations.
Concordance  between  tissue  and  blood  was  between  62%  and  87%,
despite  a median of  five months between tests.  Resistance alterations
emerged on anti-EGFR therapy. Therefore, biopsy-free, non-invasive ctDNA
analysis  provides  data  relevant  to  the  clinical  setting.  Importantly,
sequential  ctDNA  analysis  detects  patterns  of  emerging  resistance
allowing for precision planning of future therapy. 
INTRODUCTION 
Colorectal  cancer (CRC) is a heterogeneous disease that develops  as a
consequence  of  different  combinations  of  epigenetic  and  genetic
alterations,  with  significant  variability  observed  in individual  patient
prognosis and therapy response, perhaps due to molecular heterogeneity.
Advances in the treatment of patients with metastatic CRC have led to an
improvement in patient survival partly due to the use of biologic agents
targeting  the  EGFR  signaling  pathway  or  tumor  angiogenesis  (1-5).
Additionally, certain  biomarkers with prognostic or predictive value have
been identified. For example, activating mutations of KRAS and NRAS can
predict  a  lack  of  response  to  anti-EGFR  therapy.  These  mutations
frequently  co-exist  with  alterations  in  the  phosphoinositide  3-kinase
(PI3K)/Akt/mTOR pathway encoding genes (6). Hyper-mutated CRC tumors
have been found to be excellent targets for programmed death 1 (PD-1)
inhibitors  (7).  Finally,  BRAF  mutation is a known poor prognostic feature
(1, 8, 9). 
Further understanding of  underlying  genomic alterations  in  CRC has
been  made  possible  by  recent  improvements  in  DNA  sequencing
technology.  The  Cancer  Genome  Atlas  network  conducted  a
comprehensive genome-wide analysis of somatic  mutations in colorectal
tumors.  The most commonly altered genes were as follows in non-hyper-
mutated CRCs:  APC (81%),  TP53 (60%),  KRAS (43%), and PIK3CA (18%).
BRAF  mutations were  frequently  associated  with  hyper-mutated  CRCs
(10). In addition,  understanding of heterogenous genetic makeup of CRC
has led to a consensus on molecular subtypes used to classify CRC (11). 
The development of next-generation sequencing (NGS) platforms and
their   implementation  into  clinical  use  allows  for  rapid  clinical-grade
genomic analysis to identify actionable genomic alterations, and thus has
led  to  the  use  of  targeted  therapies  matched  to  patients’  specific
alterations  (12-15).  Until  recently,  genomic  sequencing  was  typically
performed on archival tumor tissue. However, acquisition of tumor tissue
is not always feasible, and a tissue biopsy at a single time point may not,
due to tumor heterogeneity, provide a recent or complete picture of the
molecular background of tumor evolution, response, and resistance  (16,
17).  One  strategy  to  overcome  these  challenges  is  to  investigate
circulating  biomarkers.  Circulating  tumor  DNA  (ctDNA)  is  shed  into
bloodstream from cancer cells and can be isolated from blood (also known
as a “liquid biopsy”)  (18-20).  More recently,  the technology has rapidly
advanced, and evaluating multiple genes by performing  NGS on ctDNA
has proven useful when applied in the clinic (21-26). 
Herein, we describe the results of ctDNA testing in 78 patients with CRC
whose blood-derived ctDNA was  interrogated by  a targeted NGS panel.
Type,  distribution,  and  frequency  of  genomic  alterations,  potential
actionability,  concordance  with  tissue testing,  and  emerging resistance
alterations detected in ctDNA after anti-EGFR-based therapy (including an
illustrative case) are described. 
MATERIALS AND METHODS
Patients
We  investigated  genomic  alterations  and  clinic-pathologic  data  from
electronic medical records in 78 consecutive patients with CRC followed at
the University of California San Diego (UCSD) Moores Cancer Center, for
whom  ctDNA  testing  was  performed  on  their  blood  samples  between
December 2014 and November 2016. This was a retrospective analysis of
all eligible patients with available data during the time period. A total of
1005 eligible patients with various cancers had ctDNA analysis during this
time period.
Next generation sequencing 
ctDNA  analyses:  Digital  sequencing  was  performed  by  clinical
laboratory  improvement  amendments  (CLIA)-licensed  and  College  of
American Pathologist (CAP)-accredited  laboratory (Guardant Health, Inc.,
http://www.guardanthealth.com/). ctDNA was extracted from whole blood
collected in 10mL Streck tubes, and 5ng-30ng of ctDNA was prepared for
sequencing as previously described  (23).  The fractional concentration or
variant allele fraction for a given somatic mutation is calculated as the
fraction of ctDNA harboring that mutation in a background of wild-type
ctDNA fragments at the same nucleotide position. Germline alterations are
filtered  out  and  not  reported.  This  ctDNA  assay  has  high  sensitivity
(detects 85%+ of the single nucleotide variants (SNVs) detected in tissue
in  advanced  cancer  patients)  and  specificity  (>  99.9999%)  (23).
Throughout the timeframe of this study, the ctDNA assay expanded gene
panels from 54 to 73 genes (Supplemental Table 1). There were 104
blood  samples  collected  from a  total  of  78  patients  in  this  study  (17
patients had multiple blood samples assayed): four samples were tested
with the 54 gene panel; 44 with the 68 gene panel; 55 with the 70 gene
panel;  and one with the 73 gene panel.  The assay reports  SNVs in all
genes  and  selects  fusions,  copy  number  variants  (CNVs),  and  indels
(Supplemental Table 1). Degree of CNVs were reported as follows: 1+,
2.13-2.40,  which  is  the 10th to  50th percentile;  2+,  2.41-4.00,  which  is
>50th to 90th percentile; and 3+, greater than 4.0 copy numbers, which is
>90th percentile. For ctDNA, the following information was evaluated; the
number of total alterations and the number of characterized alterations.
We  counted  both  variants  of  unknown  significance  (VUSs)  and
characterized alterations when we refer to total alterations.  Synonymous
alterations were not included in any analysis. 
Tumor tissue analyses: Tissue testing was performed on formalin-fixed,
paraffin-embedded  tissue  by  Foundation  Medicine  (FoundationOne,
http://www.foundationone.com),  which is  a clinical-grade NGS test  (315
genes) (27). For tissue NGS, we included only characterized alterations in
our analyses.
Concordance 
We investigated the concordance for  the 61 patients  who had both
tests  performed  (tissue  and  blood).  Concordance  between  tissue  and
blood  was  calculated  using  a  kappa  coefficient. We examined  specific
concordance rates for the most frequent alterations including TP53, KRAS,
APC, PIK3CA, BRAF and MYC, and all the genes examined were present in
the tissue and ctDNA panels.
Definition of actionability
An actionable alteration was defined by UCSD Molecular Tumor Board as a
genomic alteration that produces a protein product serving as either the
direct target or as part of a signaling pathway that could be impacted by
drugs. Drug impact could be impact or via differential expression on tumor
versus normal cells.  Drugs might be available for on-label (Food and Drug
Administration  (FDA)-approved  for  CRC)  and/or  off-label  use  (FDA-
approved  for  an  indication  other  than  CRC)  or  in  experimental  clinical
trials.  Protein  products  of  genes  were  considered  actionable  by  small
molecule  inhibitors  if  the  compound impacted the  protein  at  low 50%
inhibitory  concentrations.  Genes  that  produced  proteins  that  were
recognized  as  the  main  target  of  an  antibody  were  also  considered
actionable. We also utilized OncoKB (28) as an additional source to define
actionability.  
Statistical Design
The  study  was  performed  under  an  IRB-approved  registry  type  study
(PREDICT).   PREDICT has both prospective and retrospective components
but,  in  this  case,  data  was  gathered  retrospectively.  This  study  was
performed  in  accordance  with  the  UCSD  Moores  Cancer  Center
Institutional  Review  Board  guidelines  for  NCT02478931  and  for  any
investigational therapies to which the patients consented. 
 
RESULTS
Patient characteristics
The median age at first  blood draw was 52 years  (range,  27 to 82
years);  40  patients  (51.3%)  were  men  (Table  1).  All  patients  had  a
diagnosis  of  colorectal  adenocarcinoma.  Overall,  53 individuals  (67.9%)
had  low-grade  tumor;  11  (14.1%),  high-grade  tumor;  and  six  had
mucinous adenocarcinoma.  Regarding location,  60 patients had tumors
involving the colon (21 right colon; 36 left colon; 3 transverse colon), and
18 involved the rectum. Seventy-seven patients had stage IV disease at
the time of first blood draw; one, stage III disease. 
Genomic alterations among colorectal cancer; ctDNA results and
percentage 
The total number of genomic alterations were 310 and, of these, 214
(69.0%) were characterized alterations, including substitutions (N=148),
amplifications  (N=64),  and  indels  (N=2).  No  fusions  were  observed.
Ninety-six  alterations  (31.0%)  were  VUSs  (Table  1).  Of  the  214
characterized  alterations,  34  were  genomically  distinct,  and  119  were
molecularly distinct alterations (e.g.  TP53  R248W and TP53 R248Q were
considered genomically identical but molecularly distinct) (Supplemental
Tables 2 and 3).
Among  78  patients,  63  patients  (80.8%)  had  ctDNA  alterations
detected  with  59  (75.6%)  having  ≥1  characterized  alteration  and  48
(61.5%)  having  ≥2  characterized  alterations.   The  median  number  of
alterations  per  patient  was  3  (range,  0-26);  median  number  of
characterized alterations, 2 (range, 0-13) (Table 1).  
Focusing on characterized alterations, the most frequently altered gene
was TP53 (52.6% [41/78]) followed by KRAS (35.9% [28/78]), APC (28.2%
[22/78]), EGFR (16.7% [13/78]), BRAF (15.4% [12/78]), and PIK3CA (15.4%
[12/78]) (Figure 1, Panel A and Supplemental Table 2). 
When alterations were grouped depending on the oncogenic pathways,
genes involved in the  mitogen-activated protein kinase (MAPK)  signaling
pathway were altered in 59.0% (46/78) of patients; TP53-associated genes
were altered in 53.8% (42/78);  tyrosine kinase families were altered in
37.2% (29/78); the Wnt signaling was altered in 33.3% (26/78); the PI3K
signaling was altered in 17.9% (14/78); and cell-cycle associated genes
were altered in 14.1% (11/78) (Table 2). 
Among frequently altered genes,  APC had the highest median mutant
allele  ctDNA  fraction  of  6.6%  (range,  0.1–55.5).  Most  of  the  other
characterized mutations had a median ctDNA fraction of less than 5%.
There  was  no  clear  association  between  the  frequencies  of  gene
alterations and the fraction of ctDNA detected in the blood (Figure  1,
Panel B). 
Actionable genomic alterations among patients with CRC
We determined actionability based on our Molecular Tumor Board
assessments (Supplemental Table 4) and by OncoKB (28).
Per  our  Molecular  Tumor  Board  (UCSD)  assessment,  of  the  214
characterized  alterations,  70.1%  (150/214)  were  potentially  targetable
with  FDA-approved  drugs  as  on-label  and/or  off-label  use,  and  an
additional 26.2% (56/214) were theoretically targetable with drugs that
are currently in clinical trials. Altogether, 96.3% (206/214) were actionable
alterations that were targetable either with FDA-approved drugs or with
experimental drugs in clinical trials (Supplemental Tables 3 and 4). 
Of the 59 patients who harbored  ≥1 characterized alteration, all had
≥1  potentially  actionable  alteration.  FDA-approved,  on-label  therapies
were available for 20.5% (16/78) of patients and another 48.7% (38/78)
had  alterations  potentially  targetable  with  FDA-approved  drugs  in  a
different indication (off-label use). An additional 6.4% (5/78) of patients
had alterations theoretically targetable with experimental drugs in clinical
trials (Supplemental Figure 1, Supplemental Tables 3 and 4). 
Per  OncoKB  assessment  (http://oncokb.org/#/),  of  the  214
characterized  alterations,  5.1%  (11/214)  were  potentially  targetable
alterations for colorectal cancer and an additional 34.1% (73/214) were
theoretically  targetable  for  cancer  types  other  than  colorectal  cancer.
Altogether,  39.2%  (84/214)  were  actionable  alterations  that  were
considered to be targetable alterations (Supplemental Tables 3). Of the
59  patients  who  harbored  ≥1  characterized  alteration,  45  had  ≥1
potentially  actionable  alterations  that  were  targetable  per  OncoKB
assessment.  At  least  one  targetable  alteration  indicated  for  colorectal
cancers was found in 10.3% (8/78) of patients and another 47.4% (37/78)
had alterations that were theoretically targetable for cancer types other
than colorectal cancer (Supplemental Tables 3). 
Concordance of the ctDNA test with tissue NGS test 
Of the 78 patients who had ctDNA test, 61 patients also had a tissue
genomic test. The time between biopsy and blood draw ranged from 1 day
to 6.6 years, with a median of 5.0 months. We examined concordance for
the  most  frequent  alterations.  The  concordance  rates  were  70.5%  for
TP53, 77.0% for KRAS, 62.3% for APC, 80.3% for PIK3CA, 86.9% for BRAF,
83.6% for MYC (Table 3). There was no statistically significant difference
in  concordance  rates  in  patients  for  whom the  time  interval  between
biopsy and blood draw used for testing was ≤6 months (N = 35) versus
those for whom the time interval was >6 months (N=26).
Emerging resistance alterations in ctDNA along with therapeutic
intervention
We  documented  that  emerging  resistance  alterations  could  be
detected in ctDNA from patients treated with anti-EGFR antibodies. There
were nine patients treated with anti-EGFR-based therapy who also had
tissue  NGS  prior  to  or  soon  after  the  therapy.  Tissue  NGS  test  was
performed at various time points (range, 19 days to 26.9 months) before
the initiation of  anti-EGFR-based therapy; one patient had it  performed
one month after the initiation of the therapy (#12). Pretreatment ctDNA
was  also  available  in  two  patients,  and  both  showed  no  detectable
alterations (#1, #30) (Table 4).  
In  total,  we  observed  31  alterations  that  were  not  detected  in  the
tumor and only appeared in the ctDNA after the therapy was initiated. Of
these,  we  found  15  alterations  in  genes  known  to  be  involved  in
therapeutic  resistance  to  anti-EGFR  therapy (Table  4,  #2,  #12,  #38,
#68).  The  progression-free  survival  of  these  four  patients  were  4.6
months, 12.4 months, 6.7 months, and  2.5+ months, respectively; three
patients (#2, #12, #38) experienced disease progression at the time of
blood draw after a prior response/stable disease, and one patient (#68)
was assessed as having stable disease at the time of blood draw, but lost
to follow up thereafter.  KRAS alterations were observed in two patients
(#12,  #38);  one  patient  had five molecularly  distinct  KRAS alterations
(KRAS G12A,  KRAS G12C,  KRAS G13D,  KRAS  Q61H,  and  KRAS
amplification) and the other had KRAS amplification. Two NRAS mutations
in  one  patient  (#12)  were  observed;  NRAS  Q61H,  NRAS  Q61K.  BRAF
G469A mutation  was  observed  in  one  patient  (#12).  EGFR S492R
mutation  was  observed  in  two  patients  (#12,  #68).  Additionally,
amplifications in  ERBB2 (N = 3) (#2, #12, #38) and MET (N = 1) (#68)
were observed. 
A  representative  case  (#38)  with
emerging KRAS and ERBB2 alterations  upon  progression  on  anti-EGFR-
based therapy is presented (Figure 2).
DISCUSSION
We investigated genomic alterations in 78 patients with CRC (77, stage
IV) using a targeted NGS assay that analyzed blood-derived ctDNA. Of the
total,  63 patients  (80.8%)  had  ≥1  detectable  alteration(s),  which  is
consistent with previous reports  (23-25, 29).  Of 59 patients (75.6%) who
harbored  at  least  one  characterized  alteration,  the  most  frequent
alterations were TP53 mutations (52.6%), followed by alterations in KRAS
(35.9%), APC (28.2%), EGFR (16.7%), BRAF (15.4%), and PIK3CA (15.4%).
The mutation frequencies for KRAS and BRAF are similar to those reported
in tissue, which generally show that about 35% to 45% of patients have a
KRAS mutation (30, 31) and about 10% of patients with CRC have a BRAF
alteration (32). Examining ctDNA, Thierry et al (33) noted a higher rate of
KRAS  mutations  in  ctDNA (~59%),  while  our  rate  of  35.9% was  more
consistent  with  the  lower  range  found  in  tissue  studies.  Differences
between studies can be attributable to different sample sources (tissue
versus ctDNA in blood), relatively small sample size, technical differences
such as those in depth of sequencing, and other factors relating to the
phenotype of patients tested. 
EGFR  mutations were detected in three patients (3.8%) (two,  S492R
and  one,  G465R),  and  BRAF mutations  in  four  patients  (5.1%)  (three,
V600E  and  one,  G469A).  Several  previous  studies  have  shown  that
resistant EGFR ectodomain mutations (S492R, G465R) emerge in patients
treated with anti-EGFR therapy  (34-36). In our study, all  three patients
who  harbored  EGFR mutations  in  ctDNA  were previously  treated  with
cetuximab-based regimens, and available pretreatment tumor specimens
from  two  patients  confirmed  that  the EGFR S492R mutation  was  not
present before cetuximab treatment (Table 4).  Finding this mutation in
ctDNA has particular clinical relevance because patients with EGFR S492R
mutation appearing under the pressure of  cetuximab therapy may still
respond to panitumumab (35). 
We also examined the concordance in  the  patients who had both a
tissue and ctDNA test.  Of interest in this regard, Khan  et al,  (37) have
shown that  a  significant  proportion  of  patients  with  colorectal  cancers
defined as RAS wild-type based on tissue evaluation harbor alterations in
the RAS pathway in pretreatment cfDNA and do not benefit from EGFR
inhibitors. In  our  study,  the  concordance  rates  for  common  specific
alterations were in the range of 62.3-86.9% with a median of five months
between  tests  (Table  3).  Testing  of  ctDNA  therefore  demonstrated
acceptable concordance with NGS testing of tumor tissue obtained during
clinical  practice in  this  study.  Previous  studies  have  shown  that
concordance decreases with the temporal separation between tissue and
ctDNA  tests  (25),  but  we  did  not  observe  such  a  difference,  perhaps
because of the limited number of patients in the study.  It is also unclear
why our results showed a lower concordance for  APC compared to other
genes (62.3% versus 70.5%–86.9%); this may reflect a lower rate of APC
mutation (28.2%) in our ctDNA versus 67.2% (41/61) in tissue, perhaps
suggesting  that  APC-bearing  ctDNA  is  less  likely  to  shed  into  the
circulation. In one  study of mutation analysis in ctDNA using a targeted
NGS panel in a variety of metastatic solid tumor patients including CRC,
the concordance rate for all mutations found across 54 genes was 85.9%
between  tissue  and  ctDNA  (38).  In  another  study  of  42  patients  with
advanced-stage non-small cell lung cancer, concordance between tissue
and plasma was 76% when concordance for mutations in  EGFR, KRAS,
PIK3CA, and  TP53  was measured using a targeted sequencing  method
(39).  In  these  studies,  tissue  and  blood  sampling  were  performed
concurrently, while in our study, the time between biopsy and blood draw
ranged  from  1  day  to  6.6  years  (median  =  5.0  months).    Some
discordance between genomic profiles from tissue and ctDNA is generally
observed. On one hand, ctDNA tests  can theoretically detect shed DNA
from  multiple  tumor  sites, while  tissue  biopsy  demonstrates  only  the
alterations found at the specific site of sampling. Recent reports focusing
on discordance of the KRAS mutational status between primary tumor and
paired metastasis showed discordance rates of 3.6%–17.5% (40). On the
other hand, in cancers with small tumor burden, mutations identified in
tissue may not be detected in ctDNA test due to the low content of ctDNA.
Additionally,  emergence  of  resistance alterations can  occur  under  the
pressure of  therapy during the elapsed interval between each test  (41-
43); at the same time, targeted therapies may suppress ctDNA (44). Of
note,  we observed  that  ctDNA samples  harbor  unique  CNVs that  were
absent  from tissues.  For  instance,  amplifications  in  BRAF (N=6), KRAS
(N=3),  PIK3CA (N=3),  MET (N=2),  FGFR1  (N=2),  and  FGFR2 (N=2) were
only detected in ctDNA (not in tissue in the 61 patients who had both
tested), which, at least theoretically, may be attributed to the inadequate
representation of tumor heterogeneity by tissue testing. In contrast,  APC
mutations were more frequently detected in tissue than in ctDNA (67.2%
versus  28.2%).  Thus,  complementary  assessment  of  both  tissue  and
ctDNA appears advantageous to assess dynamic tumor profiles.
Regarding actionability to guide therapeutic decisions, per the UCSD
Molecular Tumor Board assessment,  69.2% of patients had at least one
actionable alteration that could be impacted by an FDA-approved drug,
and an additional 6.4% had alterations targetable with experimental drugs
in clinical trials.  Genes involved in the MAPK pathway,  TP53-associated
genes, tyrosine kinase families and Wnt signaling were frequently altered
(33.3-59.0%).  Although less frequent,  alterations  in  PI3K and cell  cycle
machinery were also observed (14.1-17.9%). Per OncoKB (28), the percent
of  patients  with  at  least  one  actionable  alteration  was  57.7% (45/78).
Recent actionability studies performed on ctDNA in various solid tumor
patients  reported  that  71-81.5% of  patients  had at  least  one clinically
actionable  alteration  (24,  25),  which  is  consistent  with  our  results.
Accumulating  evidence  suggests  that  biomarker-based  treatment
approach may be able to improve clinical outcome (12-15). Clinical utility
of this approach in genomically-matched patient populations continues to
be investigated in large prospective clinical trials. 
Lastly, analysis of ctDNA in serially collected plasma samples allowed
detection  of  emerging  mutant  ctDNA,  which  can  be  used  to  monitor
patients  for  disease  progression  as  well  as  to  find  mechanisms  of
resistance. In our patients treated with anti-EGFR agents, we could detect
multiple  emerging  alterations  in  genes  known  to  be  involved  in
therapeutic  resistance  to  anti-EGFR  therapy - KRAS,  NRAS,  BRAF,  and
EGFR mutations, and amplification of KRAS, ERBB2, and MET - consistent
with the implication of many of these genes in both primary as well as
acquired resistance to anti-EGFR therapy (29, 34-36, 42, 43, 45-49) (see
illustrative case,  Figure 2). A limitation of our study is that we did not
administer therapy that would impact resistant alterations; future studies
should address this issue in order to validate the role of these alterations
in resistance.  
The  study  has  additional  limitations.  Importantly,  understanding the
underlying  mechanisms  for  response  and  resistance  cannot  be  fully
elucidated in the clinic and further bench-side investigations are needed.
The median age of patients was 52, which is young for colorectal cancer,
and might  reflect a selection bias because of  the referral  pattern to a
tertiary care center or because of physician discretion in ordering ctDNA
testing.  Another  limitation  relates  to  whether  individual  mutations  are
drivers versus passengers (50).  Regarding treatment, some patients who
received  EGFR  inhibitors  in  the  current  study  were  also  given
chemotherapy. This causes some problems in interpretation of genomic
findings, although the presence of  RAS mutations is highly suggestive of
an independent effect of anti-EGFR antibodies and clonal expansion under
their selective pressure.  Finally, the timing of sample acquisition varied
as  NGS was  performed  based  on  physician  discretion.   Future  studies
would benefit from analysis at prospective, pre-defined time-points.
To conclude, over 80% of patients with advanced CRC had detectable
ctDNA alterations and more than half (76% [59/78]) per UCSD Molecular
Tumor  Board  and  57.7%  (45/78)  by  OncoKB  (28) had  potentially
actionable  alterations.  Concordance  between  tissue  and  blood  for
common specific alterations was acceptable. Additionally, we could detect
emerging resistance alterations in ctDNA from patients treated with anti-
EGFR-based therapy. These data suggest that biopsy-free,  non-invasive
ctDNA analysis  is  becoming a valuable option  when an invasive tissue
biopsy  is  not  feasible,  and  ctDNA  can  yield  promising  candidate
biomarkers for the detection and monitoring of CRC. 
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Table 1. Patient characteristics and genomic alterations in patients with
colorectal cancer
(N = 78)
Patient characteristic (N=78)
Age  at  time  of  blood  draw,  median
(range), year 52 (27-82)
Women (N (%)). 38 (48.7%)
Men (N (%)) 40 (51.3%)
Race (N (%))
Caucacian
Hispanic
Asian
Black
Other
52 (66.7%)
13 (16.7%)
7 (9.0%)
4 (5.1%)
2 (2.6%)
Tumor grade (N (%))
Well/moderately differentiated
Poorly differentiated/ undifferentiated
Mucinous adenocarcinoma
Not available 
53 (67.9%)
11 (14.1%)
6 (7.7%)
8 (10.3%)
Location of tumor
Right colon 
Left colon
Transverse colon
Rectum
21
36
3
18
Stage at the time of first blood draw
Stage III
Stage IV (N, %)
   Recurrent 
   Initially metastatic
1
77
 31 (40.3%)
 46 (59.7%)
Genomic alterations
Number of alterations* 310
Median number of alterations per patient
(range)   (includes  characterized
alterations and VUSs)
3 (0-26)
Number of characterized alterations 214 (69.0%)
Median  number  of  characterized
alterations per   patient (range)
2 (0-13)
Substitution, No. (%) 148 (47.7%)
Amplification, No. (%) 64 (20.6%)
Fusion, No. (%) 0 (0%)
Indel, No. (%) 2 (0.6%)
Variants of unknown significance, No. (%) 96 (31.0%)
* Includes both characterized alterations and variants of unknown significance
(VUSs) 
Abbreviations: NA = not available
Table  2.  Selected  actionable  genomic  alterations  and  examples  of
possible targeted   therapies (N = 78)
Genomic alteration No. (%) Example of possible targeted 
therapies* 
Tyrosine kinase families (N= 29, 37.2%)
EGFR 
substitutions/amplification
13 
(16.7%)
Afatinib, cetuximab, erlotinib
ERBB2 
substitutions/amplification
6 (7.7%) Afatinib, trastuzumab, lapatinib
FGFR1 amplification 3 (3.8%) Lenvatinib
FGFR2 amplification 3 (3.8%)
MET amplification 4 (5.1%) Cabozantinib, crizotinib
MAPK signaling (N= 46, 59.0%)
KRAS 
substitution/amplification
28 
(35.9%)
MEK inhibitor (e.g. Trametinib or 
cobimetinib)
NRAS substitution 2 (2.6%)
NF1 substitution 1 (1.3 %)
GNAS substitution 2 (2.6%)
RAF1 amplification 1 (1.3%)
BRAF 
substitution/amplification
12 
(15.4%)
BRAF inhibitor (e.g. Dabrafenib, 
vemurafenib), MEK inhibitor (e.g. 
trametinib or cobimetinib)
PI3K signaling (N= 14, 17.9%)
PIK3CA 
substitution/amplification
12 
(15.4%) mTOR inhibitor (e.g. everolimus, 
temsirolimus)PTEN substitution 1 (1.3%)
AKT1 substitution 1 (1.3%)
Cell cycle associated genes (N=11, 14.1%)
CDKN2A substitution 2 (2.6%)
Cyclin-dependent kinase inhibitor (e.g. 
Palbociclib) 
CCND1 amplification 1 (1.3%)
CCND2 amplification 2 (2.6%)
CDK4 amplification 1 (1.3%)
CDK6 amplification 4 (5.1%)
CCNE1 amplification 1 (1.3%) Proteasome inhibitor (e.g. Bortezomib)
TP53 associated genes (N= 42, 53.8%)
TP53 substitution 41 
(52.6%)
Anti-VEGF (e.g. bevacizumab), WEE1 
inhibitor (e.g. AZ1775, NCT01748825)
ATM substitution 1 (1.3%) PARP inhibitor (e.g. olaparib)
Wnt signaling (N= 26, 33.3%)
APC substitution/indel 22 
(28.2%)
COX-2 inhibitor (e.g. celecoxib) 
CTNNB1 substitution 1 (1.3%) Sorafenib, sulindac, and gamma-
secretase inhibitor
ARID1A substitution 1 (1.3%) EZH2 inhibitor (e.g. EPZ-6438 *, 
NCT01897571) 
FBXW7 substitution 2 (2.6%) mTOR inhibitor (e.g. everolimus, 
temsirolimus) 
*See Supplemental Table 4 for the rationale of possible targeted therapies.

Table 3. Concordance for specific alterations in patients with colorectal
cancer (N=61)
Specific alterations TP53 positive in
tumor
TP53 negative
in tumor
Total
TP53 positive in ctDNA 32 1 33
TP53 negative in ctDNA 17 11 28
Total 49 12 61
Concordance for TP53 43/61 (70.5%); Kappa 0.38 (SE 0.12) 
KRAS positive 
in tumor
KRAS negative
in tumor
Total 
KRAS positive in ctDNA 21 2 23
KRAS negative in 
ctDNA
12 26 38
Total 33 28 61
Concordance for KRAS 47/61 (77.0%); Kappa 0.55 (SE 0.11)
APC positive
 in tumor
APC negative
 in tumor
Total
APC positive in ctDNA 18 0 18
APC negative in ctDNA 23 20 43
Total 41 20 61
Concordance for APC 38/61 (62.3%); Kappa 0.34 (SE 0.11)
PIK3CA positive
in tumor
PIK3CA negative
in tumor
Total
PIK3CA positive in 
ctDNA
3 4 7
PIK3CA negative in 
ctDNA
8 46 54
Total 11 50 61
Concordance for 
PIK3CA
49/61 (80.3%); Kappa 0.22 (SE 0.20)
BRAF positive
 in tumor
BRAF negative
 in tumor
Total
BRAF positive in ctDNA 2 6 8
BRAF negative in 
ctDNA
2 51 53
Total 4 57 61
Concordance for BRAF 53/61 (86.9%); Kappa 0.27 (SE 0.24)
MYC positive
 in tumor
MYC negative
 in tumor
Total
MYC positive in ctDNA 2 5 7
MYC negative in ctDNA 5 49 54
Total 7 54 61
Concordance for MYC 51/61 (83.6%); Kappa 0.19 (SE 0.23)
NRAS positive
 in tumor
NRAS negative
 in tumor
Total
NRAS positive in ctDNA 1 1 2
NRAS negative in 
ctDNA
2 57 59
Total 3 58 61
Concordance for NRAS 58/61 (95.1%); Kappa 0.38 (SE 0.35)
* Only alterations with ≥ 10 patients with the anomaly are represented (except 
for NRAS which was added because of its clinical usefulness for selecting anti-
EGFR therapy). All the genes examined (TP53, KRAS, APC, PIK3CA, BRAF, MYC 
and NRAS) were present in the tissue and ctDNA panels.
Table 4: Analysis of resistant markers from anti-EGFR-based therapy with
NGS (tissue and/or liquid) (N = 9)
Cas
e
ID
Genomic 
alterations 
before anti-
EGFR
-based 
therapy (days 
before the 
initiation 
of anti-EGFR-
based 
therapy)
Regimen of 
anti-EGFR-
based 
therapy and 
clinical 
outcome
Alterations after anti-EGFR-
based therapy 
(days after the initiation of 
anti-EGFR-based therapy)
Comment
#1 ctDNA
(-30 days)
None detected
Tissue NGS
(-19 days)
CCND1 
amplification
EGFR amplification
ERBB2 
amplification
CDK6 amplification
FGF19 amplification
FGF4 amplification
MYC amplification
TOP2A 
amplification
FGF3 amplification
MUTYH Y165C
TP53 splice site 
672+1G>T
FOLFIRI plus 
panitumumab
PFS: 109 days 
(3.6 months)
Best response 
= PD with new 
metastases
Taken off due to 
progression.
ctDNA
(167 days)
CCND1 ampllification
CDK6 amplification
EGFR amplification
ERBB2 amplification
MYC amplification
PIK3CA amplification
PFS short in patient 
with 
baseline ERBB2 and 
EGFRtissue 
amplifications.
ctDNA obtained after 
progressing on anti-
EGFR-based therapy 
showed new 
PIK3CA alteration. 
#2 Tissue NGS
(-565 days)
TP53 Y163C
APC A571fs*18, 
S1421fs*52
Irinotecan plus 
cetuximab
PFS: 139 days 
(4.6 months)
Best response 
= SD (+18%)
Taken off due to 
progression.
Tissue NGS
 (144 days)
ERBB2 
amplification – 
equivocal
MYC 
amplification
 – equivocal
TP53 Y163C 
APC A571fs*18, 
S1421fs*52 
MYST3 
amplification – 
equivocal
ctDNA
(194 days)
ERBB2 amplification
CDKN2A G35W 
(0.1%)
EGFR amplification
TP53 Q317K (0.2%)
TP53 Y163C 
(75.0%)
After progressing on 
anti-EGFR-based 
therapy, 
both tissue and ctDNA 
revealed emerging 
ERBB2 
amplification. ctDNA 
also 
revealed new EGFR 
amplification.
#12 Not tested FOLFIRI plus 
cetuximab
PFS: 378 days
(12.4 months)
Tissue NGS
(30 days)
APC Y935fs*1
TP53 R282W
ctDNA 
(374 days)
APC Y935* (3.11%)
PIK3CA 
amplification
While patient was 
responding to the 
anti-EGFR-based 
therapy, 
tissue NGS revealed 
only 
Best response 
= PR (-58%)
Patient initially 
had response, 
but 
taken off due to 
progression
BRAF G469A 
(0.18%)
EGFR amplification 
EGFR S492R 
(2.68%)
ERBB2 amplification
KRAS amplification
KRAS G12A (2.15%)
KRAS G12C (0.24%)
KRAS G13D (0.25%)
KRAS Q61H (8.48%)
NRAS Q61H (5.02%)
NRAS Q61K (0.50%)
TP53 and APC 
alterations.
On progression, 
multiple
new alterations 
appeared 
including EGFR/ERBB2/
KRAS/PIK3CA 
amplifications as well 
as 
EGFR S492R, BRAF 
G469A, and activating
KRAS mutations. 
#30 ctDNA
 (-94 days)
None detected 
Tissue NGS
 (-82 days)
AKT1 E17K
BRAF V600E
CDKN2A p16INK4a 
R80* and p14ARF 
P94L
TP53 R156P
APC T1556fs*3
TERT promoter 
-124C>T
Irinotecan plus 
cetuximab
PFS: 5.8 months 
(175 days)
Best response 
= SD (+14%)
Off treatment 
due
to progression
ctDNA
(169 days)
AKT1 E17K (2.0%)
BRAF V600E (2.8%)
CDKN2A R80*(1.0%)
Tissue NGS prior to 
anti-EGFR-based 
therapy 
showed alterations in 
AKT1, BRAF and 
CDKN2A. 
These alterations were 
not apparent in ctDNA. 
However, upon 
progression on anti-
EGFR-based 
therapy, AKT1, BRAF 
and CDKN2A 
alterations were 
seen in ctDNA. 
#31 Tissue NGS
 (-806 days)
TP53 G245S
APC S1400fs*1
MUTYH G382D
Capecitabine 
plus 
cetuximab, 
followed 
by irinotecan 
plus 
cetuximab
PFS: 4.1 months 
(126 days)
Best response 
= SD (0%)
Off treatment 
due 
to progression
ctDNA
(589 days)
TP53 G245S (6.2%)
Tissue NGS and ctDNA 
analysis did not reveal 
alterations associated 
with resistance to anti-
EGFR 
treatment. However, 
genomic analysis was 
done > 500 days after 
cessation of anti-EGFR-
based 
therapy.
 
#36 Tissue NGS
(-127 days)
FANCA splice site 
1006+1G>A
FBXW7 R367*
TP53 P152fs*18, 
R158H
APC H1349fs*5, 
R213*
NOTCH1 
FOLFOX plus 
panitumumab
PFS: 1.4 months
(42 days)
Best response
= SD (0%), 
however, had 
clinical 
progression
ctDNA
(174 days)
  APC R213* (11.1%)
  TP53 R158H (11.8%)
F930fs*254
Off treatment 
due 
to progression.
#38 Tissue NGS
(-331 days)
POLE R446Q
TP53 G266V
APC E1306*
SPEN splice site 
1750-2 1750-1 ins 
A
SPTA1 R891*
FOLFOX plus 
cetuximab
PFS: 6.7 months
(202 days)
Best response 
= PR (-31%)
Off treatment 
due 
to mixed 
response (Lymph
node 
metastases were
responding, 
however, 
progression seen
in adrenal 
metastasis).
ctDNA
(232 days)
 APC E1306* (15.0%)
APC G471* (10.5%)
 BRCA2 S1064* (0.7%)
ERBB2 amplification
KRAS amplification
TP53 G266V (26.5%)
ctDNA on progression 
from anti-EGFR-based 
therapy showed new 
ERBB2 and KRAS 
alterations.
#6
7
Tissue NGS
(-88 days)
BRAF V600E
FOLFOX plus 
panitumumab
PFS: 1.4 months 
(43 days)
Best response 
= PD with new 
bone 
metastases. 
Off treatment 
due
to progression.
ctDNA
(365 days)
BRAF V600E (1.6%)
SMAD4 R361C (0.8%)
TP53 R249W (1.3%)
Baseline tissue NGS 
and 
follow up ctDNA 
showed 
persistent BRAF V600E 
mutation which could 
explain the resistance 
to 
anti-EGFR-based 
therapy.
#6
8
Tissue NGS
(-345 days)
CTNNB1 splice site 
14-1_118del106
TP53 R175H
Single agent 
cetuximab
PFS: 2.5+ 
months
(75+ days)
CT on 7/1/2016 
with stable 
disease. 
Lost to follow up.
ctDNA
(75 days)
BRAF amplification
CCNE1 amplification
EGFR S492R (0.7%)
EGFR amplification
FGFR2 amplification
MET amplification
PIK3CA amplification
RHOA Y42S (2.3%)
TP53 R175H (42.5%)
While patient was on 
anti-EGFR therapy, 
ctDNA 
showed emerging 
alterations including 
BRAF/EGFR/FGFR2/MET
/PIK3CA 
amplifications as well 
as 
resistant EGFR S492R 
mutation.
ctDNA = circulating tumor DNA, FOLFIRI = folinic acid, fluorouracil, irinotecan,
FOLFOX  =  folinic  acid,  fluorouracil,  oxaliplatin,  NGS  =  next-generation
sequencing,  PD = progressive disease,  PFS = progression-free survival,  PR =
partial response, SD = stable disease.
FIGURE LEGEND
Figure 1,  Panel  A. Frequency of  genomic  alterations  among patients
with colorectal cancer (N = 78)
Includes alterations with > 5% frequency. 
* Multiple alterations indicate that the patient had > 1 type of alteration in
the same gene (substitutions, amplifications, VUS etc). 
Abbreviations: VUS = variant of unknown significance 
Figure 1, Panel B.  Percent ctDNA among frequently  altered genes in
patients with colorectal cancer  
Depicted are seven frequently altered genes (not including amplification).
The median of % ctDNA with standard error is depicted. Presented here
are characterized alterations that were detectable. 
Figure 2.  KRAS wild-type colon cancer patient treated with anti-EGFR-
based  therapy.  ctDNA  analysis  at  progression  with  multiple  emerging
resistance alterations. 
49-year-old woman with metastatic colon cancer. Tissue NGS at diagnosis
showed alterations including TP53 and APC (Table 4, case ID #38). After
progressing on FOLFIRI plus bevacizumab, patient was started on FOLFOX
plus  cetuximab.  Patient  initially  had  response  in  left  adrenal  and
retroperitoneal  lymph  node  metastases.  However,  after  6.7  months  of
therapy, left  adrenal  node was progressing,  thus patient  was taken off
from therapy.  Post-progression ctDNA showed persistent  TP53 and  APC
alterations as well as emerging KRAS and ERBB2 amplifications. 
Left:  Pre-treatment PET/CT.  Upper figure shows left  adrenal  metastasis.
Lower figure shows retroperitoneal lymph node metastases.
Middle: Day 139 from FOLFOX plus cetuximab with response in left adrenal
and peritoneal lymph node metastases.
Right: Day 202 from FOLFOX plus cetuximab with worsening left adrenal
metastasis. 
Figure 1,  Panel  A. Frequency of  genomic  alterations  among patients
with colorectal cancer (N = 78)
Figure 1, Panel B.  Percent ctDNA among frequently  altered genes in
patients with colorectal cancer
Figure 2.  KRAS wild-type colon cancer patient treated with anti-EGFR-
based  therapy.  ctDNA  analysis  at  progression  with  multiple  emerging
resistance alterations. 
